BIOFRONTERA AG NA ON KONV
BIOFRONTERA AG NA ON KONV/ DE000A4BGGM7 /
B8FK
11.10.2024 19:31:43
|
Изменение
+0.650
|
Объем сделки |
Бид20:01:59 |
Предложение20:01:59 |
Рыночная капитализация |
Дивидендная доходность |
Коэффициент Цена/Доход |
2.895EUR
|
+28.95%
|
0 Оборот: 0.000 |
-Величина цены спроса: - |
-Величина цены предложения: - |
8.69 млнEUR |
- |
- |
Описание деятельности
Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin. Headquartered in Leverkusen, Germany, Biofrontera is a publicly listed on the Frankfurt Stock Exchange (Prime Standard) and London Stock Exchange (AIM) – B8F / ISIN: DE 0006046113. In February 2012 Biofrontera launched its prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through local partners. Ameluz® is applied in Photodynamic Therapy requiring a powerful source of red light. For this purpose Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012. As cosmeceutical products Biofrontera markets Belixos® for the regenerative care of reddened and inflamed skin. Biofrontera developed a line of cosmeceutical products for damaged skin under the Belixos brand. The product portfolio includes the Belixos® cream, Belixos LIQUID®, Belixos® GEL and DayCare cream Belixos® PROTECT.
Правление & Наблюдательный совет
Исполнительный директор |
- |
Правление |
Ludwig Lutter |
Наблюдательный совет |
Wilhelm K. T. Zours, Dr. Jörgen Tielmann, Dr. Heikki Lanckriet, Dr. Helge Lubenow, Karlheinz Schmelig, Prof. Dr. Franca Ruhwedel |
Данные компании
Имя: |
Biofrontera AG |
Адрес: |
Hemmelrather Weg 201,D-51377 Leverkusen |
Телефон: |
+49-214-87632-0 |
Факс: |
+49-214-87632-90 |
E-mail: |
info@biofrontera.com
|
Интернет: |
www.biofrontera.com |
Индустрия: |
Healthcare |
Сектор: |
Pharmaceutical Industry |
Подсектор: |
Pharmaceuticals |
Конец финансового года: |
31.12 |
Акции в свободном обращении: |
46.41% |
Дата IPO: |
- |
Связи с инвесторами
Имя: |
Anke zur Mühlen |
IR телефон: |
- |
IR-факс: |
- |
IR e-mail: |
ir@biofrontera.com
|